"Η Βιοκλινική Θεσσαλονίκης (πρώην κλινική Γαληνός), στεγάζεται σε ιδιόκτητο κτίριο δεκατριών (13) ορόφων στη συμβολή των οδών Μητροπόλεως και Μορκεντάου στο κέντρο της Θεσσαλονίκης, συνολικής επιφάνειας 4.580 τ.μ.. Είναι δυναμικότητας 150 κλινών, και διαθέτει πλήρη, υπερσύγχρονο ιατροτεχνολογικό εξοπλισμό και άριστα καταρτισμένο επιστημονικό δυναμικό. Η Βιοκλινική Θεσσαλονίκης, έχει κατορθώσει με συστηματική προσπάθεια και με την υποστήριξη του Ομίλου ΒΙΟΙΑΤΡΙΚΗ , να συνδυάσει την παροχή υψηλού επιπέδου ιατρικής και νοσηλευτικής φροντίδας από εξειδικευμένο και φιλικό ανθρώπινο δυναμικό μέσα σε ένα καλαίσθητο, σύγχρονο και φιλόξενο οικογενειακό περιβάλλον, πάντα με λογικό κόστος και με γνώμονα της ανάγκες του ασθενούς."

During the past decade, Bioclinic - Thessaloniki conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 7 clinical trials were completed, i.e. on average, 31.8% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 6 clinical trials were completed. i.e. 46.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Bioclinic - Thessaloniki" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Amgen" with 4 trials sponsored, "Hellenic Oncology Research Group" with 2 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored and "Boehringer Ingelheim" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Bioclinic - Thessaloniki" #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 1 trials as a collaborator, "European Organisation for Research and Treatment of Cancer - EORTC" with 1 trials as a collaborator and "Everest Medicines" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Bioclinic - Thessaloniki" are "Melanoma" (3 trials), "Breast Cancer" (2 trials), "Urinary Bladder Neoplasms" (2 trials), "Advanced BRAFV600 Wild-type Melanoma" (1 trials) and "Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)" (1 trials). Many other conditions were trialed in "Bioclinic - Thessaloniki" in a lesser frequency.

Most popular intervention types in "Bioclinic - Thessaloniki" are "Drug" (20 trials), "Biological" (4 trials), "Device" (1 trials), "Other" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cisplatin" (4 trials), "Gemcitabine" (4 trials), "Atezolizumab" (3 trials), "Carboplatin" (3 trials) and "Cetrelimab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Bioclinic - Thessaloniki" are 23 trials for "All" genders.

Currently, there are NaN active trials in "Bioclinic - Thessaloniki". undefined are not yet recruiting, 7 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Bioclinic - Thessaloniki, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Bioclinic - Thessaloniki, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".